Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Buy
63
INSM Quote, Financials, Valuation and Earnings
Last price:
$105.45
Seasonality move
:
-4.12%
Day range:
$99.02 - $102.81
52-week range:
$60.40 - $102.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.38x
P/B ratio:
188.61x
Volume:
4.6M
Avg. volume:
3.6M
1-year change:
58.68%
Market cap:
$18.7B
Revenue:
$363.7M
EPS (TTM):
-$5.95
Analysts' Opinion
-
Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $110.06, Insmed has an estimated upside of 7.19% from its current price of $102.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $90.00 representing 100% downside risk from its current price of $102.68.
Fair Value
-
According to the consensus of 14 analysts, Insmed has 7.19% upside to fair value with a price target of $110.06 per share.
INSM vs. S&P 500
-
Over the past 5 trading days, Insmed has overperformed the S&P 500 by 6.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Insmed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Insmed has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Insmed reported revenues of $92.8M.
Earnings Growth
-
Insmed has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Insmed reported earnings per share of -$1.42.
Enterprise value:
18.6B
EV / Invested capital:
15.45x
Price / LTM sales:
46.38x
EV / EBIT:
--
EV / Revenue:
48.84x
PEG ratio (5yr expected):
-1.25x
EV / Free cash flow:
-23.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$291.5M
Return On Assets:
-57.25%
Net Income Margin (TTM):
-265.93%
Return On Equity:
-1146.32%
Return On Invested Capital:
-85.3%
Operating Margin:
-247.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $257.5M | $315.5M | $381M | $75.5M | $92.8M | |
| Gross Profit | $200.7M | $246.3M | $291.5M | $58M | $71.5M | |
| Operating Income | -$534.3M | -$680.7M | -$859M | -$157.4M | -$229.8M | |
| EBITDA | -$496.6M | -$655.5M | -$917.9M | -$133.7M | -$232.8M | |
| Diluted EPS | -$4.27 | -$5.23 | -$5.95 | -$1.06 | -$1.42 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $501M | $756.1M | $1.1B | $758.7M | $1.4B | |
| Total Assets | $692.4M | $1.2B | $1.5B | $1.2B | $1.8B | |
| Current Liabilities | $81.4M | $125.2M | $188M | $420.9M | $239.2M | |
| Total Liabilities | $490.8M | $1B | $1.6B | $1.6B | $1.7B | |
| Total Equity | $201.6M | $119.9M | -$44.7M | -$464.8M | $99.2M | |
| Total Debt | $361.6M | $783.2M | $1.1B | $1.2B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$441.6M | -$574M | -$761.9M | -$184M | -$262.1M | |
| Cash From Investing | $108.4M | $30.1M | -$798.1M | $295.3M | $80.4M | |
| Cash From Financing | $786.4M | $171.9M | $1.4B | $3M | $29M | |
| Free Cash Flow | -$453.2M | -$588.5M | -$789.2M | -$188.7M | -$272.2M | |
INSM
Sector
Market Cap
$18.7B
$32.8M
Price % of 52-Week High
99.87%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
58.68%
-35.38%
Beta (5-Year)
0.798
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$98.57
200-day SMA
Buy
Level
$73.92
Bollinger Bands (100)
Buy
Level
67.33 - 84.07
Chaikin Money Flow
Buy
Level
22.5M
20-day SMA
Buy
Level
$81.55
Relative Strength Index (RSI14)
Buy
Level
78.76
ADX Line
Buy
Level
38.6
Williams %R
Sell
Level
-0.3913
50-day SMA
Buy
Level
$74.03
MACD (12, 26)
Buy
Level
8.62
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
173.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.869)
Sell
CA Score
(Annual)
Level (-4.9699)
Buy
Beneish M-Score
(Annual)
Level (-2.8224)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.7632)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Stock Forecast FAQ
In the current month, INSM has received 14 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INSM average analyst price target in the past 3 months is $110.06.
-
Where Will Insmed Stock Be In 1 Year?
According to analysts, the consensus estimate is that Insmed share price will rise to $110.06 per share over the next 12 months.
-
What Do Analysts Say About Insmed?
Analysts are divided on their view about Insmed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Insmed is a Sell and believe this share price will drop from its current level to $90.00.
-
What Is Insmed's Price Target?
The price target for Insmed over the next 1-year time period is forecast to be $110.06 according to 14 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INSM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Insmed is a Buy. 14 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INSM?
You can purchase shares of Insmed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Insmed shares.
-
What Is The Insmed Share Price Today?
Insmed was last trading at $105.45 per share. This represents the most recent stock quote for Insmed. Yesterday, Insmed closed at $102.68 per share.
-
How To Buy Insmed Stock Online?
In order to purchase Insmed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
How High Will Take-Two Stock Go?
Take-Two Interactive (NASDAQ:TTWO) is the video game development company behind…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
83
GMS alert for Jun 23
GMS [GMS] is up 0.03% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 16.13% over the past day.
Buy
57
GXO alert for Jun 23
GXO Logistics [GXO] is up 2.42% over the past day.
